

Stavros V Konstantinides

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/650591/publications.pdf>

Version: 2024-02-01

373
papers

39,803
citations

7069

78
h-index

2883

190
g-index

419
all docs

419
docs citations

419
times ranked

32068
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. <i>European Heart Journal</i> , 2022, 43, 940-958.	1.0	8
2	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2â€”care pathways, treatment, and follow-up. <i>European Heart Journal</i> , 2022, 43, 1059-1103.	1.0	111
3	Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. <i>Thrombosis and Haemostasis</i> , 2022, 122, 552-559.	1.8	8
4	Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1248-1263.	0.8	40
5	Reduced-Dose Intravenous Thrombolysis for Acute Intermediateâ€”High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrombolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 857-866.	1.8	35
6	Impact of Systemic Atherosclerosis on Clinical Characteristics and Short-Term Outcomes in Patients with Deep Venous Thrombosis or Thrombophlebitis. <i>American Journal of the Medical Sciences</i> , 2022, 363, 232-241.	0.4	7
7	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1â€”epidemiology, pathophysiology, and diagnosis. <i>European Heart Journal</i> , 2022, 43, 1033-1058.	1.0	80
8	Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolism. <i>Resuscitation</i> , 2022, 170, 285-292.	1.3	40
9	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 183-189.	1.0	83
10	Splanchnic vein thrombosis-related mortality in the Veneto region (Italy), 2008â€”2019: Retrospective analysis of epidemiological data. <i>Thrombosis Research</i> , 2022, 209, 41-46.	0.8	3
11	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and metaâ€”analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 409-421.	1.9	17
12	Variation of platelet function in clinical phenotypes of acute venous thromboembolism â€” Results from the GMPâ€”VTE project. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 705-715.	1.9	3
13	Diabetes mellitus and its impact on mortality rate and outcome in pulmonary embolism. <i>Journal of Diabetes Investigation</i> , 2022, 13, 725-737.	1.1	10
14	Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 209, 94-98.	0.8	34
15	Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample. <i>Viruses</i> , 2022, 14, 275.	1.5	29
16	Impact of thyroid dysfunction on short-term outcomes and long-term mortality in patients with pulmonary embolism. <i>Thrombosis Research</i> , 2022, 211, 70-78.	0.8	3
17	Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. <i>Respiration</i> , 2022, 101, 307-320.	1.2	5
18	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1â€”epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	1.8	27

#	ARTICLE	IF	CITATIONS
19	Pulmonary Embolism and Pregnancy—Challenges in Diagnostic and Therapeutic Decisions in High-Risk Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 856594.	1.1	6
20	Cardiac and Cerebral Arterial Complications of Lemierre Syndrome: Results from a Systematic Review and Individual Patient Data Meta-analysis. <i>Hamostaseologie</i> , 2022, 42, 261-267.	0.9	6
21	Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area. <i>Thrombosis Research</i> , 2022, 212, 44-50.	0.8	16
22	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. <i>Cardiovascular Research</i> , 2022, 118, 1618-1666.	1.8	32
23	Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. <i>European Heart Journal</i> , 2022, 43, 3387-3398.	1.0	69
24	Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. <i>Neurological Research and Practice</i> , 2022, 4, 16.	1.0	3
25	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. <i>American Heart Journal</i> , 2022, 251, 43-53.	1.2	59
26	EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia. <i>JCI Insight</i> , 2022, 7, .	2.3	3
27	Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e585-e593.	2.2	38
28	Temporal trends and predictors of in-hospital death in patients hospitalised for heart failure in Germany. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 990-997.	0.8	12
29	Possible misclassification of cardiovascular risk by SCORE in antisynthetase syndrome: results of the pilot multicenter study RI.CAR.D.A. <i>Rheumatology</i> , 2021, 60, 1300-1312.	0.9	8
30	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021, 9, 33-42.	5.2	100
31	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	1.9	27
32	Course of D-Dimer and C-Reactive Protein Levels in Survivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective Analysis of 577 Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 098-101.	1.8	21
33	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	1.3	23
34	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	3.1	17
35	Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score. <i>Heart</i> , 2021, 107, 549-555.	1.2	5
36	Management of Pulmonary Embolism: Results from the German Chest Pain Unit Registry. <i>Cardiology</i> , 2021, 146, 304-310.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Prognostic value of right atrial dilation in patients with pulmonary embolism. <i>ERJ Open Research</i> , 2021, 7, 00414-2020.	1.1	4
38	A review of venous thromboembolism in COVID-19: A clinical perspective. <i>Clinical Respiratory Journal</i> , 2021, 15, 506-512.	0.6	15
39	Autoimmune reactivity is present in patients with incident coronary artery ectasia. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 733-735.	0.3	2
40	Reversal of cardiopulmonary exercise intolerance in patients with post-thrombotic obstruction of the inferior vena cava. <i>Thrombosis Research</i> , 2021, 208, 219-225.	0.8	5
41	Colocalization of Erythrocytes and Vascular Calcification in Human Atherosclerosis: A Systematic Histomorphometric Analysis. <i>TH Open</i> , 2021, 05, e113-e124.	0.7	3
42	Time trends of pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-9.	0.8	8
43	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	1.2	150
44	Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us and what they don't. <i>European Respiratory Journal</i> , 2021, 58, 2101111.	3.1	20
45	Venous lactate improves the prediction of in-hospital adverse outcomes in normotensive pulmonary embolism. <i>European Journal of Internal Medicine</i> , 2021, 86, 25-31.	1.0	15
46	Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. <i>Blood</i> , 2021, 137, 2681-2693.	0.6	11
47	Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease. <i>European Respiratory Journal</i> , 2021, 58, 2004196.	3.1	14
48	Homoarginine and methylarginines independently predict long-term outcome in patients presenting with suspicion of venous thromboembolism. <i>Scientific Reports</i> , 2021, 11, 9569.	1.6	4
49	Prevalence of pulmonary embolism in 127,945 autopsies performed in cancer patients in the United States between 2003 and 2019. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1591-1593.	1.9	5
50	Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12509.	1.0	8
51	Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism. <i>Chest</i> , 2021, 159, 2428-2438.	0.4	34
52	Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12520.	1.0	27
53	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. <i>European Journal of Internal Medicine</i> , 2021, 88, 43-51.	1.0	10
54	Outcome of patients with different clinical presentations of high-risk pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 787-796.	0.4	11

#	ARTICLE	IF	CITATIONS
55	Sex differences in Lemierre syndrome: Individual patient-level analysis. <i>Thrombosis Research</i> , 2021, 202, 36-39.	0.8	3
56	COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report. <i>Hamostaseologie</i> , 2021, , .	0.9	2
57	A targeted proteomics investigation of the obesity paradox in venous thromboembolism. <i>Blood Advances</i> , 2021, 5, 2909-2918.	2.5	3
58	In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis. <i>Thrombosis Research</i> , 2021, 203, 82-84.	0.8	10
59	A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. <i>ERJ Open Research</i> , 2021, 7, 00719-2020.	1.1	14
60	Acute Pulmonary Embolism: Its Diagnosis and Treatment From a Multidisciplinary Viewpoint. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, , .	0.6	5
61	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> ,the, 2021, 8, e627-e636.	2.2	11
62	Psoriasis and its impact on the clinical outcome of patients with pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 343, 114-121.	0.8	4
63	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1255-1268.	0.7	8
64	In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 258-264.	0.4	24
65	Patients with Lemierre syndrome have a high risk of new thromboembolic complications, clinical sequelae and death: an analysis of 712 cases. <i>Journal of Internal Medicine</i> , 2021, 289, 325-339.	2.7	61
66	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	1.0	106
67	Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. <i>European Heart Journal</i> , 2020, 41, 522-529.	1.0	259
68	Duration of interventricular septal shift toward the left ventricle is associated with poor clinical outcome in precapillary pulmonary hypertension: A cardiac magnetic resonance study. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 112-117.	0.4	9
69	Temporal trends in management and outcome of pulmonary embolism: a single-centre experience. <i>Clinical Research in Cardiology</i> , 2020, 109, 67-77.	1.5	17
70	Atrial fibrillation is frequent but does not affect risk stratification in pulmonary embolism. <i>Journal of Internal Medicine</i> , 2020, 287, 100-113.	2.7	12
71	Trends in mortality related to pulmonary embolism in the European Region, 2000â€“15: analysis of vital registration data from the WHO Mortality Database. <i>Lancet Respiratory Medicine</i> ,the, 2020, 8, 277-287.	5.2	192
72	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	1.0	2,426

#	ARTICLE	IF	CITATIONS
73	Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 151-161.	1.9	42
74	Age-Dependent and -Independent Effects of Perivascular Adipose Tissue and Its Paracrine Activities during Neointima Formation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 282.	1.8	12
75	Risk factors for chronic thromboembolic pulmonary hypertension – Importance of thyroid disease and function. <i>Thrombosis Research</i> , 2020, 185, 20-26.	0.8	9
76	Activated Endothelial TGF β 1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1. <i>Circulation Research</i> , 2020, 126, 162-181.	2.0	37
77	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 707-717.	2.5	89
78	Home treatment of pulmonary embolism: are all the questions answered now after the HOME-PE trial?. <i>Cardiovascular Research</i> , 2020, 116, e179-e181.	1.8	3
79	Impact of obesity on adverse in-hospital outcomes in patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip $\text{\textcircled{R}}$ procedure - Results from the German nationwide inpatient sample. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1365-1374.	1.1	5
80	Increased interest in acute pulmonary embolism in Italy during the COVID-19 pandemic: a google trends-based analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 92-94.	1.0	4
81	EkoSonic $\text{\textcircled{R}}$ endovascular system and other catheter-directed treatment reperfusion strategies for acute pulmonary embolism: overview of efficacy and safety outcomes. <i>Expert Review of Medical Devices</i> , 2020, 17, 739-749.	1.4	11
82	Sex-specific and age-related seasonal variations regarding incidence and in-hospital mortality of pulmonary embolism in Germany. <i>ERJ Open Research</i> , 2020, 6, 00181-2020.	1.1	6
83	Venous Thromboembolism in COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1642-1653.	1.8	54
84	HElIenic Registry on Myocarditis SyndromES on behalf of Hellenic Heart Failure Association: The HERMES $\text{\textcircled{R}}$ CHF Registry. <i>ESC Heart Failure</i> , 2020, 7, 3676-3684.	1.4	5
85	Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis.. <i>European Journal of Internal Medicine</i> , 2020, 82, 29-37.	1.0	107
86	Definition of tachycardia for risk stratification of pulmonary embolism. <i>European Journal of Internal Medicine</i> , 2020, 82, 76-82.	1.0	12
87	Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism. <i>ESC Heart Failure</i> , 2020, 7, 4061-4070.	1.4	10
88	Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute venous thromboembolism – results from clinical observation studies. <i>EBioMedicine</i> , 2020, 60, 102978.	2.7	22
89	Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH. <i>ERJ Open Research</i> , 2020, 6, 00356-2020.	1.1	6
90	Potential Drug Interactions between Recombinant Interleukin-2 and Direct Oral Anticoagulants: Indirect Evidence from In Vivo Animal Studies. <i>Hamostaseologie</i> , 2020, 40, 679-686.	0.9	1

#	ARTICLE	IF	CITATIONS
91	Thrombosis and thromboembolism related to COVID-19: A clarion call for obtaining solid estimates from large-scale multicenter data. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 741-743.	1.0	6
92	Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) Trial. <i>European Respiratory Journal</i> , 2020, 56, 2000663.	3.1	8
93	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1456.	1.0	21
94	Management of acute pulmonary embolism 2019: what is new in the updated European guidelines?. <i>Internal and Emergency Medicine</i> , 2020, 15, 957-966.	1.0	10
95	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
96	Letter by Tziakas et al Regarding Article, "Aortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targets". <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, e180-e181.	1.1	0
97	Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1143-1146.	1.8	30
98	Fatality rates and use of systemic thrombolysis in pregnant women with pulmonary embolism. <i>ESC Heart Failure</i> , 2020, 7, 2365-2372.	1.4	18
99	The optimal imaging test for diagnosis of acute pulmonary embolism: a second chance for lung scintigraphy?. <i>European Respiratory Journal</i> , 2020, 55, 2001426.	3.1	2
100	Thrombosis and Thromboembolism Related to COVID-19. <i>JACC: Case Reports</i> , 2020, 2, 1388-1390.	0.3	5
101	Uncertain Value of High-sensitive Troponin T for Selecting Patients With Acute Pulmonary Embolism for Outpatient Treatment by Hestia Criteria. <i>Academic Emergency Medicine</i> , 2020, 27, 1043-1046.	0.8	9
102	Validation of a fast prognostic score for risk stratification of normotensive patients with acute pulmonary embolism. <i>Clinical Research in Cardiology</i> , 2020, 109, 1008-1017.	1.5	36
103	2019 ESC guidelines on pulmonary embolism: Novelties and unanswered questions. <i>European Journal of Internal Medicine</i> , 2020, 74, 1-4.	1.0	4
104	Traps N' Clots: NET-Mediated Thrombosis and Related Diseases. <i>Thrombosis and Haemostasis</i> , 2020, 120, 373-383.	1.8	22
105	Venous thromboembolism in patients hospitalized for hip joint replacement surgery. <i>Thrombosis Research</i> , 2020, 190, 1-7.	0.8	8
106	Isolated Pulmonary Embolism Is Associated With a High Risk of Arterial Thrombotic Disease. <i>Chest</i> , 2020, 158, 341-349.	0.4	11
107	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
108	Predicting Venous Thromboembolism in Primary Care. <i>Thrombosis and Haemostasis</i> , 2020, 120, 531-533.	1.8	0

#	ARTICLE	IF	CITATIONS
109	Chronic thromboembolic disease following pulmonary embolism: more work ahead. <i>European Respiratory Journal</i> , 2020, 55, 2000229.	3.1	5
110	Severe Hemorrhage Associated With Oral Anticoagulants. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, 312-319.	0.6	12
111	Where to treat patients with acute pulmonary embolism?. <i>Kardiologia Polska</i> , 2020, 78, 15-19.	0.3	5
112	Venous thromboembolism in patients hospitalized for knee joint replacement surgery. <i>Scientific Reports</i> , 2020, 10, 22440.	1.6	9
113	Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?. <i>European Respiratory Journal</i> , 2020, 55, 1902323.	3.1	1
114	High-sensitivity troponin I for risk stratification in normotensive pulmonary embolism. <i>ERJ Open Research</i> , 2020, 6, 00625-2020.	1.1	3
115	Whatâ€™s new in severe pulmonary embolism?. <i>Intensive Care Medicine</i> , 2019, 45, 75-77.	3.9	8
116	A prospective cohort study to identify and evaluate endotypes of venous thromboembolism: Rationale and design of the Genotyping and Molecular Phenotyping in Venous ThromboEmbolism project (GMP-VTE). <i>Thrombosis Research</i> , 2019, 181, 84-91.	0.8	14
117	Increased Lymphangiogenesis and Lymphangiogenic Growth Factor Expression in Perivascular Adipose Tissue of Patients with Coronary Artery Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1000.	1.0	12
118	Quality of life and functional limitations after pulmonary embolism and its prognostic relevance. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1923-1934.	1.9	39
119	The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. <i>European Heart Journal</i> , 2019, 40, 3453-3455.	1.0	220
120	Survival Benefit of Obese Patients With Pulmonary Embolism. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1960-1973.	1.4	30
121	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Respiratory Journal</i> , 2019, 54, 1901647.	3.1	806
122	Response to â€Detecting right ventricular dysfunction in patients diagnosed with low-risk pulmonary embolism: is routine computed tomographic pulmonary angiography sufficient?â€™. <i>European Heart Journal</i> , 2019, 40, 3357-3358.	1.0	2
123	The Membership Committee of the ESC. <i>Cardiovascular Research</i> , 2019, 115, e130-e132.	1.8	0
124	Optimizing the Personalized, Risk-Adjusted Management of Pulmonary Embolism: An Integrated Clinical Trial Programme. <i>Hamostaseologie</i> , 2019, 39, 117-127.	0.9	4
125	Center for Thrombosis and Hemostasis Mainz. <i>European Heart Journal</i> , 2019, 40, 1827-1829.	1.0	0
126	Evaluation of the predictive value of the bleeding prediction score VTEâ€BLEED for recurrent venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 364-371.	1.0	11

#	ARTICLE	IF	CITATIONS
127	Potential Involvement of Osteopontin in Inflammatory and Fibrotic Processes in Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1332-1346.	1.8	13
128	Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2019, 9, 7145.	1.6	17
129	Sex-specific differences in pulmonary embolism. <i>Thrombosis Research</i> , 2019, 178, 173-181.	0.8	15
130	Prediction and prognostic importance of in-hospital major bleeding in a real-world cohort of patients with pulmonary embolism. <i>International Journal of Cardiology</i> , 2019, 290, 144-149.	0.8	19
131	Recurrence Risk after First Symptomatic Distal versus Proximal Deep Vein Thrombosis According to Baseline Risk Factors. <i>TH Open</i> , 2019, 03, e58-e63.	0.7	15
132	Lysed Erythrocyte Membranes Promote Vascular Calcification. <i>Circulation</i> , 2019, 139, 2032-2048.	1.6	37
133	AB0691...INCREASED CARDIOVASCULAR RISK IN MIXED CONNECTIVE TISSUE DISEASE: EVALUATION OF MACROVASCULAR INVOLVEMENT AND ITS PREDICTORS BY AORTIC PULSE WAVE VELOCITY. , 2019, , .		2
134	Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis. <i>Hamostaseologie</i> , 2019, 39, 076-086.	0.9	30
135	Therapeutic Advances in Emergency Cardiology: Acute Pulmonary Embolism. <i>American Journal of Therapeutics</i> , 2019, 26, e248-e256.	0.5	3
136	Power of the Wilcoxon-Mann-Whitney test for non-inferiority in the presence of death-censored observations. <i>Biometrical Journal</i> , 2019, 61, 1187-1200.	0.6	0
137	The Prognostic Value of Renal Function in Acute Pulmonary Embolism—A Multi-Centre Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 140-148.	1.8	24
138	Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2019, 40, 902-910.	1.0	179
139	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	1.5	44
140	Endothelial Leptin Receptor Deletion Promotes Cardiac Autophagy and Angiogenesis Following Pressure Overload by Suppressing Akt/mTOR Signaling. <i>Circulation: Heart Failure</i> , 2019, 12, e005622.	1.6	35
141	Magnetic resonance direct thrombus imaging for pre-operative assessment of acute thrombosis in chronic thromboembolic pulmonary hypertension. <i>European Heart Journal</i> , 2019, 40, 944-944.	1.0	9
142	Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2019, 173, 166-171.	0.8	32
143	Long-term impact of acute kidney injury on prognosis in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 283, 48-54.	0.8	27
144	Treatment of the antiphospholipid syndrome with direct oral anticoagulants. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 483-486.	0.6	18

#	ARTICLE	IF	CITATIONS
145	Incidence and in-hospital safety outcomes of patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip: five-year German national patient sample including 13,575 implants. <i>EuroIntervention</i> , 2019, 14, 1725-1732.	1.4	38
146	High cardiovascular risk in mixed connective tissue disease: evaluation of macrovascular involvement and its predictors by aortic pulse wave velocity. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 994-1002.	0.4	3
147	Detection and treatment of chronic thromboembolic pulmonary hypertension: Still a lot of homework to do. <i>Hellenic Journal of Cardiology</i> , 2018, 59, 24-25.	0.4	6
148	Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism. <i>European Respiratory Journal</i> , 2018, 51, 1800077.	3.1	14
149	Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials. <i>European Respiratory Journal</i> , 2018, 51, 1701775.	3.1	38
150	Global public awareness about atrial fibrillation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 49-57.	1.0	9
151	Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study. <i>European Respiratory Journal</i> , 2018, 51, 1702037.	3.1	30
152	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 128-131.	0.8	4
153	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018, 39, 4208-4218.	1.0	267
154	Diagnosis of recurrent venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 229-235.	0.8	14
155	Prevention of early complications and late consequences after acute pulmonary embolism: Focus on reperfusion techniques. <i>Thrombosis Research</i> , 2018, 164, 163-169.	0.8	8
156	Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 250-258.	0.3	32
157	Medical Management of Pulmonary Embolism. , 2018, , 371-387.		0
158	Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. <i>European Respiratory Journal</i> , 2018, 52, 1801687.	3.1	78
159	Pulmonary Embolism: Contemporary Medical Management and Future Perspectives. <i>Annals of Vascular Diseases</i> , 2018, 11, 265-276.	0.2	3
160	Sex-specific differences in the distal versus proximal presenting location of acute deep vein thrombosis. <i>Thrombosis Research</i> , 2018, 172, 74-79.	0.8	18
161	Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, 4186-4195.	1.0	55
162	Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 69-78.	0.8	140

#	ARTICLE	IF	CITATIONS
163	The endothelial tumor suppressor p53 is essential for venous thrombus formation in aged mice. <i>Blood Advances</i> , 2018, 2, 1300-1314.	2.5	16
164	Pulmonary embolism. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18028.	18.1	208
165	Diagnosis of Cerebral Venous Thrombosis: The Complementary Value of Imaging Methods. <i>Thrombosis and Haemostasis</i> , 2018, 118, 956-956.	1.8	0
166	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	13.9	205
167	Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: A Meta-Analysis. <i>Current Vascular Pharmacology</i> , 2018, 16, 179-189.	0.8	43
168	A five-year, single-centre experience on ultrasound-assisted, catheter-directed thrombolysis in patients with pulmonary embolism at high risk and intermediate to high risk. <i>EuroIntervention</i> , 2018, 14, 1136-1143.	1.4	23
169	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017, 38, ehw597.	1.0	83
170	Systemic Thrombolytic Therapy for Acute Pulmonary Embolism: Who Is a Candidate?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 056-065.	0.8	17
171	Risk-adapted management of pulmonary embolism. <i>Thrombosis Research</i> , 2017, 151, S92-S96.	0.8	18
172	Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1436-1442.	1.9	53
173	Diagnosis of pulmonary embolism: progress after many YEARS. <i>Lancet, The</i> , 2017, 390, 210-211.	6.3	3
174	Perivascular adipose tissue: epiphenomenon or local risk factor?. <i>International Journal of Obesity</i> , 2017, 41, 1311-1323.	1.6	18
175	COMPARISON OF CIN RISK PREDICTION MODELS: A PROSPECTIVE COHORT STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1363.	1.2	0
176	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1536-1544.	1.2	258
177	A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. <i>Pharmacogenomics</i> , 2017, 18, 23-34.	0.6	10
178	The Elusive Evidence for Inferior Vena Cava Filters to Prevent Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1598-1600.	1.2	6
179	Novel echocardiographic prognostic markers for cardiac tamponade in patients with large malignant pericardial effusions: A paradigm shift from flow to tissue imaging. <i>Echocardiography</i> , 2017, 34, 1315-1323.	0.3	4
180	Interferon lambda1/IL29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation. <i>Journal of Pathology</i> , 2017, 243, 111-122.	2.1	79

#	ARTICLE	IF	CITATIONS
181	Impact of World Thrombosis Day campaign. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 138-141.	1.0	2
182	Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosis. Scientific Reports, 2017, 7, 4591.	1.6	26
183	C-terminal fragment of agrin (CAF) levels predict acute kidney injury after acute myocardial infarction. BMC Nephrology, 2017, 18, 202.	0.8	8
184	Temporal Trends in the Prevalence of Infective Endocarditis in Germany Between 2005 and 2014. American Journal of Cardiology, 2017, 119, 317-322.	0.7	76
185	Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: Results From a Single-Center Cohort. Angiology, 2017, 68, 433-440.	0.8	13
186	External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 1164-1170.	1.8	71
187	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thrombosis and Haemostasis, 2017, 117, 2425-2434.	1.8	9
188	From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 2017, 117, 769-783.	1.8	53
189	Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. Drug Metabolism and Personalized Therapy, 2017, 32, 183-190.	0.3	2
190	Venous thromboembolism: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1219-1229.	1.8	88
191	Absence of transforming growth factor beta 1 in murine platelets reduces neointima formation without affecting arterial thrombosis. Thrombosis and Haemostasis, 2017, 117, 1782-1797.	1.8	9
192	Catheter-directed thrombolysis for acute pulmonary embolism: Where do we stand?. Lung India, 2017, 34, 221.	0.3	2
193	Venous thromboembolism: A Call for risk assessment in all hospitalised patients. Thrombosis and Haemostasis, 2016, 116, 777-779.	1.8	29
194	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Thrombosis and Haemostasis, 2016, 116, 191-197.	1.8	38
195	Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?. Thrombosis and Haemostasis, 2016, 115, 233-235.	1.8	29
196	Relationship Between Arterial Access and Outcomes in STâ€Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STRategic Reperfusion Early After Myocardial Infarction (STREAM) Study. Journal of the American Heart Association, 2016, 5, .	1.6	5
197	Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. European Respiratory Journal, 2016, 48, 780-786.	3.1	199
198	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	2.9	455

#	ARTICLE	IF	CITATIONS
199	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
200	Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. <i>European Respiratory Journal</i> , 2016, 48, 1369-1376.	3.1	159
201	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 600-609.	1.0	50
202	Trends in pregnancy outcomes in patients with pulmonary hypertension: still a long way to go. <i>European Journal of Heart Failure</i> , 2016, 18, 1129-1131.	2.9	14
203	Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. <i>Thrombosis and Haemostasis</i> , 2016, 115, 827-834.	1.8	30
204	Differences between perivascular adipose tissue surrounding the heart and the internal mammary artery: possible role for the leptin-inflammation-fibrosis-hypoxia axis. <i>Clinical Research in Cardiology</i> , 2016, 105, 887-900.	1.5	48
205	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , 2016, 144, 62-68.	0.8	47
206	Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 787-794.	0.2	26
207	Comparison of risk assessment strategies for not-high-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 47, 1170-1178.	3.1	66
208	Trends in Pulmonary Embolism Outcomes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 171-173.	1.2	17
209	Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 121-128.	1.9	129
210	Management of Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 976-990.	1.2	258
211	Outcome of patients with right heart thrombi: the Right Heart Thrombi European Registry. <i>European Respiratory Journal</i> , 2016, 47, 869-875.	3.1	77
212	Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 312-320.	1.0	53
213	Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2015, 148, 211-218.	0.4	85
214	Progress in the management of acute pulmonary embolism. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 417-424.	1.2	9
215	Acute phase treatment of venous thromboembolism: advanced therapy. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1202-1209.	1.8	5
216	Management of intermediate-risk pulmonary embolism: uncertainties and challenges. <i>European Journal of Haematology</i> , 2015, 95, 489-497.	1.1	14

#	ARTICLE	IF	CITATIONS
217	Global public awareness of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1365-1371.	1.9	106
218	Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project. <i>BMJ Open</i> , 2015, 5, e008157.	0.8	19
219	History of deep vein thrombosis is a discriminator for concomitant atrial fibrillation in pulmonary embolism. <i>Thrombosis Research</i> , 2015, 136, 899-906.	0.8	25
220	Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. <i>European Heart Journal</i> , 2015, 36, 1405-1414.	1.0	324
221	Spot urine albumin to creatinine ratio outperforms novel acute kidney injury biomarkers in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 197, 48-55.	0.8	21
222	Risk stratification of normotensive pulmonary embolism based on the sPESI " Does it work for all patients?. <i>International Journal of Cardiology</i> , 2015, 197, 162-163.	0.8	21
223	Evaluation of oral anticoagulation therapy: Rationale and design of the thrombEVAL study programme. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 622-628.	0.8	16
224	Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism. <i>European Respiratory Journal</i> , 2015, 45, 1323-1331.	3.1	34
225	Theme 4: Invasive management of (recurrent) VTE and PTS. <i>Thrombosis Research</i> , 2015, 136, S19-S25.	0.8	6
226	Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin. <i>European Respiratory Journal</i> , 2015, 46, 1701-1710.	3.1	38
227	External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. <i>Thrombosis Research</i> , 2015, 135, 796-801.	0.8	50
228	Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2015, 36, 605-614.	1.0	382
229	Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. <i>European Respiratory Journal</i> , 2015, 45, 201-210.	3.1	82
230	A novel H-FABP assay and a fast prognostic score for risk assessment of normotensive pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2014, 112, 996-1003.	1.8	56
231	Thrombosis: A major contributor to global disease burden. <i>Thrombosis and Haemostasis</i> , 2014, 112, 843-852.	1.8	28
232	Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. <i>European Respiratory Journal</i> , 2014, 43, 1669-1677.	3.1	121
233	Thrombosis: A major contributor to global disease burden. <i>Thrombosis Research</i> , 2014, 134, 931-938.	0.8	119
234	Thrombosis: A Major Contributor to Global Disease Burden. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 724-735.	1.5	103

#	ARTICLE	IF	CITATIONS
235	Thrombosis: a major contributor to the global disease burden. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1580-1590.	1.9	343
236	Lipoprotein apheresis reduces biomarkers of plaque destabilization and cardiovascular risk. <i>Journal of Clinical Apheresis</i> , 2014, 29, 235-242.	0.7	4
237	CardioPulse. <i>European Heart Journal</i> , 2014, 35, 3145-3151.	1.0	192
238	Management of pulmonary embolism: recent evidence and the new European guidelines. <i>European Respiratory Journal</i> , 2014, 44, 1385-1390.	3.1	11
239	Fibrinolysis for Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 371, 579-582.	13.9	27
240	Risk-Adapted Management of Acute Pulmonary Embolism: Recent Evidence, New Guidelines. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0040.	0.4	4
241	Asthma and pulmonary embolism: bringing airways and vessels closer together. <i>European Respiratory Journal</i> , 2014, 43, 694-696.	3.1	5
242	Validation of a New Risk Score to Predict Contrast-Induced Nephropathy After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1487-1493.	0.7	39
243	Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions?. <i>Annals of Medicine</i> , 2014, 46, 672-678.	1.5	51
244	Management of venous thrombo-embolism: an update. <i>European Heart Journal</i> , 2014, 35, 2855-2863.	1.0	355
245	The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. <i>Blood Reviews</i> , 2014, 28, 221-226.	2.8	296
246	Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2363-2371.	1.1	659
247	Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. <i>European Respiratory Journal</i> , 2014, 44, 694-703.	3.1	186
248	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
249	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 370, 1402-1411.	13.9	1,221
250	Derivation and Validation of Multimarker Prognostication for Normotensive Patients with Acute Symptomatic Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 718-726.	2.5	164
251	Mechanisms Linking Leptin to Arterial and Venous Thrombosis: Potential Pharmacological Targets. <i>Current Pharmaceutical Design</i> , 2014, 20, 635-640.	0.9	18
252	Acute Phase Treatment of Pulmonary Embolism. <i>Current Vascular Pharmacology</i> , 2014, 12, 393-400.	0.8	4

#	ARTICLE	IF	CITATIONS
253	Importance of leptin signaling and signal transducer and activator of transcription-3 activation in mediating the cardiac hypertrophy associated with obesity. <i>Journal of Translational Medicine</i> , 2013, 11, 170.	1.8	44
254	Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens. <i>Clinical Research in Cardiology Supplements</i> , 2013, 8, 38-45.	2.0	1
255	A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. <i>New England Journal of Medicine</i> , 2013, 369, 2304-2312.	13.9	210
256	Development of an easily applicable risk score model for contrast-induced nephropathy prediction after percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2013, 163, 46-55.	0.8	74
257	A simple score for rapid risk assessment of non-high-risk pulmonary embolism. <i>Clinical Research in Cardiology</i> , 2013, 102, 73-80.	1.5	51
258	Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: Modulatory effects of rosuvastatin. <i>International Journal of Cardiology</i> , 2013, 170, 173-181.	0.8	19
259	Differential Effect of Baseline Adiponectin on All-Cause Mortality in Hemodialysis Patients Depending on Initial Body Mass Index. Long-Term Follow-Up Data of 4.5 Years. , 2013, 23, 45-56.		18
260	Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. <i>Obesity</i> , 2013, 21, 461-468.	1.5	151
261	Leptin promotes neointima formation and smooth muscle cell proliferation via NADPH oxidase activation and signalling in caveolin-rich microdomains. <i>Cardiovascular Research</i> , 2013, 99, 555-565.	1.8	37
262	The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism. <i>Thrombosis Research</i> , 2013, 132, 543-547.	0.8	9
263	Reduction of the radiation dose received by interventional cardiologists following training in radiation protection. <i>Radiation Protection Dosimetry</i> , 2013, 155, 119-121.	0.4	13
264	Leptin-Dependent and Leptin-Independent Paracrine Effects of Perivascular Adipose Tissue on Neointima Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 980-987.	1.1	57
265	BMI-independent inverse relationship of plasma leptin levels with outcome in patients with acute pulmonary embolism. <i>International Journal of Obesity</i> , 2013, 37, 204-210.	1.6	12
266	Pulmonary embolism hotline 2012. <i>Hamostaseologie</i> , 2013, 33, 43-50.	0.9	4
267	The right ventricle revisited. <i>Hellenic Journal of Cardiology</i> , 2013, 54, 419-21.	0.4	1
268	Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 62-71.	0.8	23
269	Leptin Locally Synthesized in Carotid Atherosclerotic Plaques Could Be Associated With Lesion Instability and Cerebral Emboli. <i>Journal of the American Heart Association</i> , 2012, 1, e001727.	1.6	32
270	Is it time for home treatment of pulmonary embolism?. <i>European Respiratory Journal</i> , 2012, 40, 742-749.	3.1	36

#	ARTICLE	IF	CITATIONS
271	Leptin promotes the mobilization of vascular progenitor cells and neovascularization by NOX2-mediated activation of MMP9. <i>Cardiovascular Research</i> , 2012, 93, 170-180.	1.8	44
272	A Strategy Combining Imaging and Laboratory Biomarkers in Comparison With a Simplified Clinical Score for Risk Stratification of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2012, 141, 916-922.	0.4	75
273	Multidetector CT Scan for Acute Pulmonary Embolism. <i>Chest</i> , 2012, 142, 1417-1424.	0.4	90
274	Pulmonary embolism: risk assessment and management. <i>European Heart Journal</i> , 2012, 33, 3014-3022.	1.0	118
275	Red blood cell distribution width "a strong prognostic marker in cardiovascular disease" is associated with cholesterol content of erythrocyte membrane. <i>Clinical Hemorheology and Microcirculation</i> , 2012, 51, 243-254.	0.9	57
276	Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: Rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>American Heart Journal</i> , 2012, 163, 33-38.e1.	1.2	106
277	The Right Ventricle in Health and Disease: Insights into Physiology, Pathophysiology and Diagnostic Management. <i>Cardiology</i> , 2012, 121, 263-273.	0.6	52
278	Usefulness of Matrix Metalloproteinase-9 Plasma Levels to Identify Patients With Preserved Left Ventricular Systolic Function After Acute Myocardial Infarction Who Could Benefit from Eplerenone. <i>American Journal of Cardiology</i> , 2012, 110, 1085-1091.	0.7	20
279	Thrombolytic therapy for submassive pulmonary embolism. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 379-389.	0.7	17
280	Effect of the Factor Xa Inhibitor Rivaroxaban on Arterial Thrombosis in Wild-Type and Apolipoprotein E-Deficient Mice. <i>Thrombosis Research</i> , 2012, 130, 793-798.	0.8	13
281	Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure. <i>Quality of Life Research</i> , 2012, 21, 143-153.	1.5	12
282	Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. <i>Thorax</i> , 2011, 66, 75-81.	2.7	115
283	Mortality Risk Assessment and the Role of Thrombolysis in Pulmonary Embolism. <i>Critical Care Clinics</i> , 2011, 27, 953-967.	1.0	22
284	Erythrocyte Duffy antigen receptor for chemokines (DARC): diagnostic and therapeutic implications in atherosclerotic cardiovascular disease. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 417-424.	2.8	18
285	Effect of smoking cessation on the number and adhesive properties of early outgrowth endothelial progenitor cells. <i>International Journal of Cardiology</i> , 2011, 152, 61-69.	0.8	20
286	Adipokines and thrombosis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2011, 38, 864-871.	0.9	44
287	Lipidapheresis improves microcirculation of the upper limbs. <i>Journal of Clinical Apheresis</i> , 2011, 26, 167-173.	0.7	11
288	Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. <i>European Heart Journal</i> , 2011, 32, 1657-1663.	1.0	188

#	ARTICLE	IF	CITATIONS
289	A New Method to Diagnose Pulmonary Embolism: David against Goliath(s). American Journal of Respiratory and Critical Care Medicine, 2011, 184, 626-627.	2.5	2
290	Effects of Exercise Training on the Severity and Composition of Atherosclerotic Plaque in apoE-Deficient Mice. Journal of Vascular Research, 2011, 48, 347-356.	0.6	38
291	Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism. Circulation, 2011, 124, 2716-2724.	1.6	219
292	Update on the cardiovascular risk in obesity: endocrine and paracrine role of the adipose tissue. Hellenic Journal of Cardiology, 2011, 52, 327-36.	0.4	9
293	Diagnosis of early myocarditis after respiratory or gastrointestinal tract viral infection: insights from cardiovascular magnetic resonance. Clinical Research in Cardiology, 2010, 99, 707-714.	1.5	20
294	Thrombolysis for pulmonary embolism: Past, present and future. Thrombosis and Haemostasis, 2010, 103, 877-883.	1.8	30
295	Leptin Enhances the Potency of Circulating Angiogenic Cells Via Src Kinase and Integrin $\alpha 5 \beta 1$. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 200-206.	1.1	70
296	Overexpression of Integrin $\alpha 5 \beta 1$ Enhances the Paracrine Properties of Circulating Angiogenic Cells via Src Kinase-Mediated Activation of STAT3. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1398-1406.	1.1	36
297	Mortality Risk Assessment and the Role of Thrombolysis in Pulmonary Embolism. Clinics in Chest Medicine, 2010, 31, 759-769.	0.8	12
298	Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. European Heart Journal, 2010, 31, 1836-1844.	1.0	183
299	Effects of Obesity and Weight Loss on the Functional Properties of Early Outgrowth Endothelial Progenitor Cells. Journal of the American College of Cardiology, 2010, 55, 357-367.	1.2	61
300	Elevated Heart-Type Fatty Acid-Binding Protein Levels on Admission Predict an Adverse Outcome in Normotensive Patients With Acute Pulmonary Embolism. Journal of the American College of Cardiology, 2010, 55, 2150-2157.	1.2	126
301	Tenecteplase can be given to patients with intermediate-risk pulmonary embolism " But should it?. Thrombosis Research, 2010, 126, e407-e408.	0.8	4
302	The Diagnosis and Treatment of Acute Pulmonary Embolism. Deutsches Ärztblatt International, 2010, 107, 589-95.	0.6	47
303	Fibrinolysis for Pulmonary Embolism. , 2010, , 351-361.		0
304	Desmoteplase in acute massive pulmonary thromboembolism. Thrombosis and Haemostasis, 2009, 101, 557-562.	1.8	29
305	Prolactin as a modulator of platelet function and thrombosis: The end of the story, or a new beginning?. Thrombosis and Haemostasis, 2009, 101, 991-992.	1.8	4
306	Non-invasive imaging in the diagnosis of acute viral myocarditis. Clinical Research in Cardiology, 2009, 98, 753-763.	1.5	51

#	ARTICLE	IF	CITATIONS
307	Statin Use is Associated with a Significant Reduction in Cholesterol Content of Erythrocyte Membranes. A Novel Pleiotropic Effect?. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 471-480.	1.3	21
308	Thrombolysis for hemodynamically stable patients with pulmonary embolism: Still searching for the intermediate-risk group. <i>Thrombosis Research</i> , 2009, 124, 647-648.	0.8	5
309	Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. <i>Atherosclerosis</i> , 2009, 205, 63-73.	0.4	23
310	Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315.	1.0	2,645
311	Leptin receptor is elevated in carotid plaques from neurologically symptomatic patients and positively correlated with augmented macrophage density. <i>Journal of Vascular Surgery</i> , 2008, 48, 1146-1155.	0.6	15
312	Acute Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2008, 359, 2804-2813.	13.9	225
313	Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 1330.	0.4	11
314	Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-dependent mechanisms and TNF α involvement. <i>Thrombosis Research</i> , 2008, 122, 366-375.	0.8	45
315	Cigarette Smoke Exposure Promotes Arterial Thrombosis and Vessel Remodeling after Vascular Injury in Apolipoprotein E-Deficient Mice. <i>Journal of Vascular Research</i> , 2008, 45, 480-492.	0.6	19
316	Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1018-1025.	2.5	158
317	Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2008, 31, 1024-1029.	3.1	62
318	Leptin Enhances the Recruitment of Endothelial Progenitor Cells Into Neointimal Lesions After Vascular Injury by Promoting Integrin-Mediated Adhesion. <i>Circulation Research</i> , 2008, 103, 536-544.	2.0	92
319	Acute pulmonary embolism revisited. <i>Postgraduate Medical Journal</i> , 2008, 84, 651-658.	0.9	18
320	Massive Pulmonary Embolism: What Level of Aggression?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 047-055.	0.8	20
321	Thrombolysis during cardiopulmonary resuscitation should be addressed in guidelines for pulmonary embolism: reply. <i>European Heart Journal</i> , 2008, 29, 3067-3068.	1.0	313
322	Recurrent venous thromboembolism: Quite harmless after all?. <i>Thrombosis and Haemostasis</i> , 2008, 99, 655-656.	1.8	1
323	Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1123-1129.	1.8	34
324	Risikostratifikation und differenzierte Therapiekonzepte auf der Intensivstation bei Patienten mit akuter Lungenembolie. , 2008, , 84-92.		0

#	ARTICLE	IF	CITATIONS
325	Large emboli on their way through the heart – First live demonstration of large paradoxical embolisms through a patent foramen ovale. <i>European Journal of Echocardiography</i> , 2007, 8, 158-160.	2.3	5
326	Leptin signalling and leptin-mediated activation of human platelets: Importance of JAK2 and the phospholipases C β 2 and A2. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1063-1071.	1.8	37
327	Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice. <i>Thrombosis and Haemostasis</i> , 2007, 98, 220-227.	1.8	18
328	Possible Gender-Related Differences in the Risk-to-Benefit Ratio of Thrombolysis for Acute Submassive Pulmonary Embolism. <i>American Journal of Cardiology</i> , 2007, 99, 103-107.	0.7	66
329	Expression of the leptin receptor in different types of vascular lesions. <i>Histochemistry and Cell Biology</i> , 2007, 128, 323-333.	0.8	34
330	Contemporary Diagnostic Algorithm for the Hemodynamically Unstable Patient With Suspected Massive Pulmonary Embolism. , 2007, , 105-108.		0
331	Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases C γ 2 and A2. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1063-71.	1.8	8
332	Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina – The role of GNB3 C825T polymorphism. <i>American Heart Journal</i> , 2006, 151, 870-877.	1.2	23
333	Distinct antithrombotic consequences of platelet glycoprotein Ib α and VI deficiency in a mouse model of arterial thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2014-2021.	1.9	91
334	Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. <i>European Heart Journal</i> , 2006, 27, 386-392.	1.0	216
335	Plasminogen Activator Inhibitor-1 From Bone Marrow – Derived Cells Suppresses Neointimal Formation After Vascular Injury in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1254-1259.	1.1	24
336	Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. <i>European Heart Journal</i> , 2006, 28, 224-229.	1.0	119
337	Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA. <i>Thrombosis and Haemostasis</i> , 2006, 95, 857-864.	1.8	9
338	Pulmonary embolism: impact of right ventricular dysfunction. <i>Current Opinion in Cardiology</i> , 2005, 20, 496-501.	0.8	83
339	Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2290-2295.	1.9	17
340	Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. <i>Thrombosis and Haemostasis</i> , 2005, 93, 145-152.	1.8	39
341	Thrombolytic Treatment of Acute Pulmonary Embolism: Toward the End of a Long-Lasting Debate?. , 2005, , 13-22.		0
342	Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. <i>European Respiratory Journal</i> , 2005, 25, 843-848.	3.1	179

#	ARTICLE	IF	CITATIONS
343	N-Terminal Pro-Brain Natriuretic Peptide or Troponin Testing Followed by Echocardiography for Risk Stratification of Acute Pulmonary Embolism. <i>Circulation</i> , 2005, 112, 1573-1579.	1.6	286
344	Exercise Training Reduces Neointimal Growth and Stabilizes Vascular Lesions Developing After Injury in Apolipoprotein E-Deficient Mice. <i>Circulation</i> , 2004, 109, 386-392.	1.6	64
345	Leptin Promotes Vascular Remodeling and Neointimal Growth in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 112-117.	1.1	212
346	Inhibition of Endogenous Leptin Protects Mice From Arterial and Venous Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2196-2201.	1.1	86
347	PAI-1 and vasculopathy: the debate continues. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 13-15.	1.9	4
348	Should Thrombolytic Therapy Be Used in Patients with Pulmonary Embolism?. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 69-74.	1.0	27
349	Accidental left ventricular placement of a defibrillator probe due to a patent foramen ovale in arrhythmogenic right ventricular dysplasia. <i>Acta Cardiologica</i> , 2004, 59, 449-451.	0.3	2
350	Exercise Training Leads To A significant Reduction In Luminal Stenosis And Neointimal Formation After Vascular Injury In Apolipoprotein E-deficient Mice. <i>Medicine and Science in Sports and Exercise</i> , 2004, 36, S22.	0.2	0
351	Thrombolysis in submassive pulmonary embolism? Yes. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1127-1129.	1.9	38
352	Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 2097-2103.	1.1	82
353	Importance of Cardiac Troponins I and T in Risk Stratification of Patients With Acute Pulmonary Embolism. <i>Circulation</i> , 2002, 106, 1263-1268.	1.6	398
354	Do PAI-1 and Vitronectin Promote or Inhibit Neointima Formation?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1943-1945.	1.1	39
355	Different Mechanisms of Increased Luminal Stenosis After Arterial Injury in Mice Deficient for Urokinase- or Tissue-Type Plasminogen Activator. <i>Circulation</i> , 2002, 106, 1847-1852.	1.6	77
356	Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2002, 347, 1143-1150.	13.9	947
357	The case for thrombolysis in acute major pulmonary embolism: hemodynamic benefits and beyond. <i>Intensive Care Medicine</i> , 2002, 28, 1547-1551.	3.9	5
358	Disruption of the plasminogen activator inhibitor-1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. <i>FASEB Journal</i> , 2001, 15, 1840-1842.	0.2	166
359	Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice. <i>Circulation</i> , 2001, 103, 576-583.	1.6	155
360	The Prothrombotic Effects of Leptin. <i>Annals of the New York Academy of Sciences</i> , 2001, 947, 134-142.	1.8	49

#	ARTICLE	IF	CITATIONS
361	Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. <i>Journal of Clinical Investigation</i> , 2001, 108, 1533-1540.	3.9	305
362	Thrombolytic treatment of pulmonary embolism: Life-saving option or unacceptable risk?. , 2000, , 183-191.		0
363	Submassive and Massive Pulmonary Embolism: A Target for Thrombolytic Therapy?. <i>Thrombosis and Haemostasis</i> , 1999, 82, 104-108.	1.8	47
364	Cerebral and Renal Embolization after Lymphography in a Patient with Non-Hodgkin Lymphoma: Case Report. <i>Radiology</i> , 1999, 210, 381-383.	3.6	16
365	Comparison of alteplase versus heparin for resolution of major pulmonary embolism. <i>American Journal of Cardiology</i> , 1998, 82, 966-970.	0.7	159
366	Patent Foramen Ovale Is an Important Predictor of Adverse Outcome in Patients With Major Pulmonary Embolism. <i>Circulation</i> , 1998, 97, 1946-1951.	1.6	379
367	Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism: Results of a Multicenter Registry. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1165-1171.	1.2	936
368	Noninvasive estimation of right ventricular systolic pressure in postinfarction ventricular septal rupture. <i>Critical Care Medicine</i> , 1997, 25, 1167-1174.	0.4	8
369	Association Between Thrombolytic Treatment and the Prognosis of Hemodynamically Stable Patients With Major Pulmonary Embolism. <i>Circulation</i> , 1997, 96, 882-888.	1.6	403
370	Role of Cardiac Ultrasound in the Detection of Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1996, 17, 39-49.	0.8	13
371	A Comparison of Surgical and Medical Therapy for Atrial Septal Defect in Adults. <i>New England Journal of Medicine</i> , 1995, 333, 469-473.	13.9	380
372	Mobile thrombi in atherosclerotic lesions of the thoracic aorta: The diagnostic impact of transesophageal echocardiography. <i>American Heart Journal</i> , 1993, 126, 707-710.	1.2	44
373	Modulators of Nitric Oxide-Dependent Osteoinductive Activity of Human Red Blood Cells. <i>TH Open</i> , 0, , .	0.7	0